Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,342 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal Saline Clear all
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Withdrawn Phase 1 Interventional

Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity

NCT00942838
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma
Interventions
Cisplatin, Whole Abdomen Radiotherapy
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 17, 2026, 5:14 PM EDT
Withdrawn Early Phase 1 Interventional

Intraductal Liposomal Bupivacaine for Chronic Pancreatitis

NCT04611958
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
ERCP with Bupivacaine infusion
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

NCT00583778
View directory record Official record
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

NCT04845178
View directory record Official record
Conditions
Migraine
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 17, 2026, 5:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
View directory record Official record
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
View directory record Official record
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
View directory record Official record
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043
View directory record Official record
Conditions
Supportive, Ill-defined Sites
Interventions
paclitaxel, docetaxel, taxane, taxane
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

NCT00133978
View directory record Official record
Conditions
Critical Illness, Sepsis, Multiple Organ Failure
Interventions
Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo
Other
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848
View directory record Official record
Conditions
Fibroids, Uterine, Leiomyoma
Interventions
Saline, EN3835
Other · Drug
Lead sponsor
Advance Biofactures Corporation
Industry
Eligibility
35 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

MANP in Hypertension and Metabolic Syndrome

NCT03781739
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
MANP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical and Surgical Treatment of Teeth With Periodontal Disease

NCT05252000
View directory record Official record
Conditions
Periodontal Diseases
Interventions
mechanical debridement, adjunctive aPDT, sham aPDT
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

NCT01888367
View directory record Official record
Conditions
Surgical Site Infections
Interventions
DFA-02 Antibiotic Gel, DFA-02 Placebo Gel
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
31
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Study Assessing Pain Relief After Replacement of the Knee

NCT06799845
View directory record Official record
Conditions
Total Knee Arthroplasty (Postoperative Pain)
Interventions
ATX101, bupivacaine hydrochloride, saline placebo
Drug
Lead sponsor
Allay Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Little Rock, Arkansas • Tamarac, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 17, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

NCT02872428
View directory record Official record
Conditions
Shock,Hemorrhagic, Trauma
Interventions
Valproic Acid, Isotonic saline solution
Drug
Lead sponsor
Dr. Hasan Alam
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 17, 2026, 5:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 17, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficlatuzumab, Cetuximab, Placebo
Biological · Other
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 17, 2026, 5:14 PM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 17, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer

NCT02672098
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Hyperthermic intraperitoneal chemotherapy (HIPEC), Carboplatin
Procedure · Drug
Lead sponsor
Loma Linda University
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 5:14 PM EDT